USE OF OXALIPLATIN (ELOXATIN®) IN PATIENTS WITH RENAL FAILURE
- Authors: Besova N.1
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
- Issue: Vol 23, No 11 (2012)
- Pages: 35-38
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115555
- ID: 115555
Cite item
Open Access
Access granted
Abstract
Platinum drugs are widely used in oncology care. However, the use of cisplatin is limited by its nephrotoxicity that is absent in the third-generation platinum derivative oxaliplatin. There are pharmacokinetic, pharmacogenetic, and clinical data that substantiate that oxaliplatin may be prescribed for patients with insignificantly or moderately reduced kidney function (creatinine clearance > 20 ml/min).
Keywords
Full Text
About the authors
N. Besova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Email: besovans@mail.ru
Candidate of Medical Sciences Moscow
References
- Graham M., Lockwood G., Greenslade D. et al. Clinical Pharmacokinetics of Oxaliplatin. A Critical Review // Clin. Cancer Res. - 2000; 6: 1205-18.
- Takimoto C., Graham M., Lockwood G. et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function // Clin. Cancer Res. - 2007; 13: 4832-9.
- Massari C., Brienza S., Rotarski M. et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function // Cancer Chemother. Pharmacol. - 2000; 45: 157-64.
- Takimoto C., Remick C., Sharma S. et al. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study // J. Clin. Oncol. - 2003; 21: 2664-72.
- Моисеев А. А. Фармакогенетика препаратов платины // Онкогинекология. -2012; 2: 2-12
- Burger H., Loos W., Eechoute K. et al. Drug transporters of platinum-based anticancer agents and their clinical significance // Drug. Resist. Updat. - 2011; 14: 22-34.
- Burger H., Zoumaro-Djayoon A., Boersma A. et al. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2) // Br. J. Pharmacol. - 2010; 159: 898-908.
- Yonezawa A., Inui K. Organic cation transporter OCT/SLC22A and H+/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents // Biochem. Pharmacol. - 2011; 81: 563-8.
- Jong N., Nakanishi T., Liu J. et al. Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons // J. Pharmacol. Exp. Ther. - 2011; 338: 537-47.
Supplementary files
